The course of cancer related fatigue up to ten years in early breast cancer patients. What impact in clinical practice? [PDF]
, 2017 Little is known about the cancer related fatigue (CRF) along cancer course and risk factors that could predict CRF development and persistence in breast cancer (BC) survivors.
Cognetti, F. +5 more
core +1 more source
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]
, 2015 Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F +16 more
core +2 more sources
Neo-adjuvant and adjuvant chemotherapy of gastric cancer
Annals of Oncology, 2007 Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgery is the primary curative treatment of locoregional gastric cancer. In Western countries, however, at the time of resection, most patients are expected to have regional lymph node involvement with poor prognostic ...
DE VITA, Ferdinando +8 more
openaire +4 more sources
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]
, 2011 Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W. +27 more
core +1 more source
Neo-adjuvant and adjuvant chemotherapy in bladder cancer
Annals of Oncology, 2007 Transitional cell carcinoma of the bladder represents the second most common genitourinary malignancy [1]; the clinical approach to muscle-invasive disease has been modified in the last decade, considering the important role of multidisciplinary team, including surgeon, oncologist and radiotherapist.
D'AURIA, GIULIANA +6 more
openaire +3 more sources
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. [PDF]
, 2017 PurposeTumor levels of thymidylate synthase (TS), a target of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer, have been studied as a predictive or prognostic biomarker with mixed results.Patients and methodsTumor TS levels were ...
Bertagnolli, Monica M +13 more
core +1 more source
Adjuvant chemotherapy of bladder cancer
Annals of Oncology, 2006 Bladder cancer is one of the most common genitourinary cancer. 1/3 of patients presents with invasive disease. Radical cystectomy is the standard treatment for patients with muscle invasive disease: although local treatment can be curative, about 50% of patients will develop distant metastases.
BOCCARDO, FRANCESCO, PALMERI L.
openaire +3 more sources
Current perspective - Trastuzumab [PDF]
, 2009 This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core +1 more source
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer [PDF]
, 2012 Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer. Patients and Methods: The ADEBAR trial was a multicenter phase Ill trial in which patients with lymph
Aivazova-Fuchs, Viktoria +16 more
core +1 more source
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group [PDF]
, 2017 Background: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). Patients and methods: Data from 237 SS patients recorded in the database of the French Sarcoma Group were ...
Blay, J.-Y +14 more
core